AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Entropy Neurodynamics Limited

0.039

+0.0024.00%

Volume:2.66M

Turnover:101.44K

Market Cap:63.61M

PE:-12.56

High:0.039

Open:0.038

Low:0.038

Close:0.038

52wk High:0.046

52wk Low:0.025

Shares:1.63B

Float Shares:878.05M

Volume Ratio:1.85

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.003

EPS(LYR):-0.004

ROE:-92.06%

ROA:-45.59%

PB:8.00

PE(LYR):-10.00

Loading ...

Overview Company News Filings

Entropy Neurodynamics Says Strategic Agreement Signed with CDMO Biocina

Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%

MT Newswires Live

Entropy Neurodynamics Ltd - Agreement Establishes Key Foundation for Broader International Development and Commercialisation of Trp-8803

THOMSON REUTERS

Entropy Neurodynamics - Strategic Agreement Signed with Tga-Licensed, FDA- and Ema-Aligned CDMO Biocina to Manufacture Trp-8803

THOMSON REUTERS

Entropy Neurodynamics - Dosing in Initial Cohorts Anticipated Before End of Cy2026

THOMSON REUTERS

Entropy Neurodynamics - Patient Recruitment to Commence, First Dosing Expected Later This Quarter

THOMSON REUTERS

Entropy Neurodynamics - Secures Hrec Approval for Phase 1B/2a 8-Indication Basket Study of Trp-8803

THOMSON REUTERS

Entropy Neurodynamics - Enters Clinical Trial Research Agreement with Swinburne University for World-First Trial

THOMSON REUTERS

Entropy Neurodynamics - to Evaluate Trp-8803 Across Eight Major Disorders in Single Clinical Framework

THOMSON REUTERS

Entropy Neurodynamics Wins Ethics Approval for 72-Patient TRP-8803 Basket Trial

Entropy Neurodynamics Gets Ethics Committee Approval to Evaluate Psilocin Formulation Across Eight Disorders; Shares Rise 3%

MT Newswires Live

Entropy Neurodynamics Requests Trading Halt

Entropy Neurodynamics - Trading Halt Pending Announcement on Hrec Approval of 8803 Study

THOMSON REUTERS

Entropy Neurodynamics Ltd-appointment of Joint Company Secretary

THOMSON REUTERS

Entropy Neurodynamics Granted South African Patent for Fibromyalgia Treatment Using Psilocybin

MT Newswires Live

Entropy Neurodynamics Ltd-south Africa Grants Enp Broad Fibromyalgia Patent to 2043

THOMSON REUTERS

Entropy Neurodynamics Granted Australian Patent for Psilocin Crystalline Forms

MT Newswires Live

Entropy Neurodynamics Ltd-additional Australian Patent Granted

THOMSON REUTERS

Entropy Neurodynamics' Binge Eating Disorder Drug Candidate Meets Primary Endpoint in Phase 2 Trial; Shares Gain 6%

MT Newswires Live

Entropy Neurodynamics Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ENP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","market":"AU","secType":"STK","nameCN":"Entropy Neurodynamics Limited","latestPrice":0.039,"timestamp":1787292720000,"preClose":0.0375,"halted":0,"volume":2656197,"delay":0,"changeRate":0.040000000000000036,"nameEN":"Entropy Neurodynamics Limited","floatShares":878046607,"shares":1631064683,"eps":-0.003104,"marketStatus":"Market Closed","change":0.0015,"latestTime":"08-21 16:12:00 AEST","open":0.038,"high":0.039,"low":0.038,"amount":101437,"amplitude":0.026667,"askPrice":0.04,"askSize":1408817,"bidPrice":0.038,"bidSize":157894,"shortable":3,"etf":0,"ttmEps":-0.003104,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.0375,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.851010168336109,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ENP.AU","preClose":0.0375,"auctionPrice":0.039,"auctionVolume":25000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292481595}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","floatShares":878046607,"roa":"-45.59%","roe":"-92.06%","lyrEps":-0.0039,"volumeRatio":1.851010168336109,"shares":1631064683,"dividePrice":0,"high":0.039,"amplitude":0.026667,"preClose":0.0375,"low":0.038,"week52Low":0.025,"pbRate":"8.00","psRate":"40.22","week52High":0.046,"institutionHeld":0,"latestPrice":0.039,"committee":-0.798439,"eps":-0.003104,"divideRate":0,"volume":2656197,"delay":0,"ttmEps":-0.003104,"open":0.038,"prevYearClose":0.033,"prevWeekClose":0.036,"prevMonthClose":0.035,"prevQuarterClose":0.032,"fiveDayClose":0.036,"twentyDayClose":0.037,"sixtyDayClose":0.031},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660156694","title":"Entropy Neurodynamics Says Strategic Agreement Signed with CDMO Biocina","url":"https://stock-news.laohu8.com/highlight/detail?id=2660156694","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660156694?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:20","pubTimestamp":1787102427,"startTime":"0","endTime":"0","summary":"BRIEF-Entropy Neurodynamics Says Strategic Agreement Signed With CDMO BiocinaAug 19 (Reuters)-Entropy Neurodynamics LtdENP.AX:STRATEGIC AGREEMENT SIGNED WITH TGA-LICENSED, FDA- AND EMA-ALIGNED CDMO BI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nFWN44F0Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241324","title":"Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241324","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241324?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:01","pubTimestamp":1787101292,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement  provides the manufacturing capability to support clinical trials and future regulatory requirements.The company's shares climbed nearly 3% in recent trading on Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660812490","title":"Entropy Neurodynamics Ltd - Agreement Establishes Key Foundation for Broader International Development and Commercialisation of Trp-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2660812490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660812490?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:20","pubTimestamp":1787091658,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0Z2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490816","title":"Entropy Neurodynamics - Strategic Agreement Signed with Tga-Licensed, FDA- and Ema-Aligned CDMO Biocina to Manufacture Trp-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490816","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490816?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:20","pubTimestamp":1787091658,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554484","title":"Entropy Neurodynamics - Dosing in Initial Cohorts Anticipated Before End of Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554484?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:07","pubTimestamp":1785852456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44119G:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554179","title":"Entropy Neurodynamics - Patient Recruitment to Commence, First Dosing Expected Later This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554179?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:07","pubTimestamp":1785852456,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44119G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554124","title":"Entropy Neurodynamics - Secures Hrec Approval for Phase 1B/2a 8-Indication Basket Study of Trp-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554124?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:07","pubTimestamp":1785852456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44119G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656544825","title":"Entropy Neurodynamics - Enters Clinical Trial Research Agreement with Swinburne University for World-First Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656544825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656544825?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:07","pubTimestamp":1785852456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44119G:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656541225","title":"Entropy Neurodynamics - to Evaluate Trp-8803 Across Eight Major Disorders in Single Clinical Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=2656541225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656541225?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:07","pubTimestamp":1785852456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44119G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656697554","title":"Entropy Neurodynamics Wins Ethics Approval for 72-Patient TRP-8803 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656697554","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656697554?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:00","pubTimestamp":1785852040,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics wins ethics approval for 72-patient TRP-8803 basket trialEntropy Neurodynamics secured Human Research Ethics Committee clearance to start a Phase 1b/2a basket trial of TRP-8803, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLck52B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656358685","title":"Entropy Neurodynamics Gets Ethics Committee Approval to Evaluate Psilocin Formulation Across Eight Disorders; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656358685","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656358685?lang=en_us&edition=fundamental","pubTime":"2026-08-04 09:36","pubTimestamp":1785807402,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  secured human research ethics committee approval for a phase 1b/2a study to evaluate TRP-8803 across eight major disorders under a single clinical framework, according to a Tuesday filing with the Australian bourse.Indications for the basket study in 72 patients include anorexia nervosa, body dysmorphic disorder, obsessive-compulsive disorder, generalized anxiety disorder, post-traumatic stress disorder, treatment-resistant depression, fibromyalgia, and irritable bowel syndrome.The company entered into a clinical trial research agreement with Swinburne University to support the study. Patient recruitment is due to start shortly across all indications, with first patient dosing expected later in the current quarter and dosing in initial cohorts anticipated before the end of the year.The indications were selected based on the \"growing clinical evidence\" supporting the therapeutic potential of TRP-8803, which is Entropy's proprietary intravenously administered psilo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655382567","title":"Entropy Neurodynamics Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2655382567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655382567?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:18","pubTimestamp":1785453488,"startTime":"0","endTime":"0","summary":"BRIEF-Entropy Neurodynamics Requests Trading HaltJuly 31 (Reuters)-Entropy Neurodynamics LtdENP.AX:TRADING HALT PENDING ANNOUNCEMENT ON HREC APPROVAL OF 8803 STUDYFurther company coverage:ENP.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W2IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655568382","title":"Entropy Neurodynamics - Trading Halt Pending Announcement on Hrec Approval of 8803 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2655568382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655568382?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:17","pubTimestamp":1785453461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W2IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653070305","title":"Entropy Neurodynamics Ltd-appointment of Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2653070305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653070305?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:06","pubTimestamp":1784866005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUEBTP3CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652265468","title":"Entropy Neurodynamics Granted South African Patent for Fibromyalgia Treatment Using Psilocybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2652265468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652265468?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:25","pubTimestamp":1784510734,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said it was granted a patent in South Africa covering methods of treating fibromyalgia using psilocybin, with a term extended to September 2043, according to a Monday Australian bourse filing.The patent provides broad intellectual property protection covering the clinical use of psilocybin for the treatment of fibromyalgia, including therapeutic methods, dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy, and manufacture.The patent term is subject to the payment of annual renewal fees.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652500322","title":"Entropy Neurodynamics Ltd-south Africa Grants Enp Broad Fibromyalgia Patent to 2043","url":"https://stock-news.laohu8.com/highlight/detail?id=2652500322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652500322?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:36","pubTimestamp":1784500563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nTUE1X4F4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650197000","title":"Entropy Neurodynamics Granted Australian Patent for Psilocin Crystalline Forms","url":"https://stock-news.laohu8.com/highlight/detail?id=2650197000","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650197000?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:16","pubTimestamp":1783642613,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said the Australian Patent Office has granted it an Australian patent titled Psilocin Crystalline Forms, providing composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve its stability, solubility, and pharmaceutical properties, according to a Friday Australian bourse filing.The company said the patent claims also cover manufacturing methods, pharmaceutical formulations, and therapeutic applications across a range of neuropsychiatric disorders, with the patent remaining in force until September 2043.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VAP.AU","USRD","BBOZ.AU","IOZ.AU","DACE.AU","BK7096","GIVE.AU","QFN.AU","QRE.AU","STW.AU","EIGA.AU","OZF.AU","VAS.AU","ENP.AU","XJO.AU","IISV.AU","E200.AU","OZR.AU","IMLC.AU","IIGF.AU","XAO.AU","BEAR.AU","XKO.AU","GEAR.AU","SLF.AU","ZYAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650970848","title":"Entropy Neurodynamics Ltd-additional Australian Patent Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2650970848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650970848?lang=en_us&edition=fundamental","pubTime":"2026-07-10 07:07","pubTimestamp":1783638457,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUE4PVVPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649609807","title":"Entropy Neurodynamics' Binge Eating Disorder Drug Candidate Meets Primary Endpoint in Phase 2 Trial; Shares Gain 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649609807","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649609807?lang=en_us&edition=fundamental","pubTime":"2026-07-07 12:56","pubTimestamp":1783400177,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said its TRP-8803 drug candidate met the primary endpoint in the first group of a phase 2 trial in treatment-resistant binge eating disorder, with 50% of patients in complete remission and all patients seeing clinically meaningful improvement, according to a Tuesday filing with the Australian bourse.All first group patients achieved the trial's primary and secondary efficacy endpoints, experiencing a 74% reduction in binge eating episodes alongside \"significant\" improvements across symptom severity, per the filing.An independent data and safety monitoring board has approved the trial's progression to the second group, which is fully enrolled with a study baseline period to start this quarter and final results expected in the fourth quarter.The top line results also support the expansion of Entropy's precision-controlled psychedelic platform into additional neuropsychiatric indications, the company said.Shares of Entropy Neurodynamics rose past 6% in recent Tuesda","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648639485","title":"Entropy Neurodynamics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2648639485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648639485?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:10","pubTimestamp":1783033804,"startTime":"0","endTime":"0","summary":"BRIEF-Entropy Neurodynamics Seeks Trading HaltJuly 3 (Reuters)-Entropy Neurodynamics LtdENP.AX:TRADING HALT PENDING ANNOUNCEMENT ON BINGE EATING DISORDER STUDY DATAFurther company coverage:ENP.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}